STOCK TITAN

[Form 4] NeueHealth, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

NeueHealth, Inc. (NEUE) reported a Section 16 Form 4 showing that director Kedrick D. Adkins Jr. recorded a disposition of 16,443 shares of common stock on 10/02/2025 and now holds 0 shares of the public common stock following the transaction. The filing explains that on 10/02/2025 the company completed a merger in which NH Holdings 2025, Inc. acquired the issuer and the issuer became a wholly-owned subsidiary of the acquiring parent.

Under a Rollover Agreement effective at the merger time, the reporting person contributed previously held common stock and Series A and Series B preferred shares into NH Holdings 2025 SPV, L.P. in exchange for corresponding units of the private buyer, resulting in the reported public share disposition. The form is signed by an attorney-in-fact on behalf of the reporting person and documents the change in beneficial ownership tied to the merger and rollover transaction.

NeueHealth, Inc. (NEUE) ha riportato un modulo della Sezione 16, Modulo 4 che mostra che il direttore Kedrick D. Adkins Jr. ha registrato una disposizione di 16,443 azioni ordinarie in data 10/02/2025 e ora detiene 0 azioni delle azioni ordinarie pubbliche a seguito della transazione. La comunicazione spiega che in 10/02/2025 la società ha completato una fusione in cui NH Holdings 2025, Inc. ha acquisito l'emittente e quest'ultimo è diventato una controllata interamente posseduta della capogruppo acquirente.

Sotto un Rollover Agreement efficace al momento della fusione, la persona che riporta ha conferito azioni ordinarie precedentemente detenute e azioni privilegiate di Serie A e Serie B in NH Holdings 2025 SPV, L.P. in cambio di unità corrispondenti del comprador privato, risultando nella disposizione pubblica delle azioni riportate. Il modulo è firmato da un procuratore-in-fatto per conto della persona che riporta e documenta la variazione della proprietà beneficiaria legata all'operazione di fusione e rollover.

NeueHealth, Inc. (NEUE) informó de un Formulario 4 de la Sección 16 que muestra que el director Kedrick D. Adkins Jr. registró una disposición de 16,443 acciones comunes en la fecha 10/02/2025 y ahora posee 0 acciones de las acciones comunes públicas tras la transacción. El escrito explica que en 10/02/2025 la empresa completó una fusión en la que NH Holdings 2025, Inc. adquirió al emisor y este pasó a ser una subsidiaria de propiedad total de la empresa adquirente.

Con un Rollover Agreement vigente en el momento de la fusión, la persona que reporta aportó acciones comunes previamente poseídas y acciones preferentes Serie A y Serie B a NH Holdings 2025 SPV, L.P. a cambio de unidades correspondientes del comprador privado, resultando en la disposición de las acciones públicas reportadas. El formulario está firmado por un apoderado en nombre de la persona que reporta y documenta el cambio de titularidad beneficiaria vinculado a la fusión y al acuerdo de rollover.

NeueHealth, Inc. (NEUE)는 섹션 16 폼 4를 통해 이사 Kedrick D. Adkins Jr.가 16,443 주의 보통주를 매각한 것을 기록했으며 거래 이후 공개 보통주를 0 주 보유하게 되었음을 보고했습니다. 본 공시는 10/02/2025에 NH Holdings 2025, Inc.가 발행자를 인수했고 발행자가 인수 자회사인 인수 모회사의 wholly-owned 자회사가 되었음을 설명합니다.

합병 시점에 발효된 Rollover Agreement에 따라 보고자는 이전에 보유하던 보통주와 시리즈 A 및 시리즈 B 우선주를 NH Holdings 2025 SPV, L.P.에 기여하고, 이에 상응하는 비공개 매수자의 유닛을 받았으며, 이로 인해 보고된 공개 주식 처분이 발생했습니다. 본 양식은 보고자 대리인에 의해 서명되었으며 합병 및 롤오버 거래와 관련된 수익 소유권의 변화를 문서화합니다.

NeueHealth, Inc. (NEUE) a déclaré, dans un Formulaire 4 de la Section 16, qu’un administrateur, Kedrick D. Adkins Jr., a enregistré une cession de 16 443 actions ordinaires à la date 10/02/2025 et ne détient désormais plus aucune action des actions ordinaires publiques à la suite de la transaction. Le dépôt précise que le 10/02/2025 la société a réalisé une fusion par laquelle NH Holdings 2025, Inc. a acquis l’émetteur et que celui-ci est devenu une filiale entièrement détenue par la société mère acquéreur.

Sous un Rollover Agreement en vigueur au moment de la fusion, la personne déclarant a apporté des actions ordinaires détenues précédemment ainsi que des actions privilégiées de série A et B dans NH Holdings 2025 SPV, L.P. en échange d’unités correspondantes de l’acheteur privé, ce qui a entraîné la disposition des actions publiques déclarées. Le formulaire est signé par un mandataire agissant au nom de la personne déclarant et documente le changement de propriété bénéficiaire lié à la fusion et à l’opération de rollover.

NeueHealth, Inc. (NEUE) meldete ein Section 16 Form 4, das zeigt, dass Direktor Kedrick D. Adkins Jr. eine Veräußerung von 16.443 Stammaktien am 10/02/2025 registrierte und infolgedessen 0 Aktien der öffentlichen Stammaktien nach der Transaktion hält. Die Einreichung erklärt, dass am 10/02/2025 das Unternehmen eine Fusion abgeschlossen hat, bei der NH Holdings 2025, Inc. den Emittenten erworben hat und dieser eine vollständig Tochtergesellschaft der erwerbenden Dachgesellschaft wurde.

Unter einer zum Zeitpunkt der Fusion wirksamen Rollover Agreement hat die meldende Person zuvor gehaltene Stammaktien sowie Serie-A- und Serie-B-Privat-Anteile in NH Holdings 2025 SPV, L.P. eingebracht und dafür entsprechende Einheiten des privaten Käufers erhalten, was zur gemeldeten Veräußerung der öffentlichen Anteile führte. Das Formular ist von einem Bevollmächtigten im Auftrag der meldenden Person unterzeichnet und dokumentiert die Änderung des wirtschaftlichen Eigentums im Zusammenhang mit der Fusion und der Rollover-Transaktion.

NeueHealth, Inc. (NEUE) أبلغت عن نموذج من القسم 16 (Form 4) يبيّن أن المدير Kedrick D. Adkins Jr. سجّل تصريفًا لـ 16,443 من الأسهم العادية في تاريخ 10/02/2025 وهو الآن لا يحمل أي أسهم من الأسهم العادية العامة عقب الصفقة. يشرح التسجيل أنه في 10/02/2025 أُنجزت صفقة اندماج استحوذت فيها NH Holdings 2025, Inc. على المُصدر وأصبح المُصدر فرعًا مملوكًا كليًا للمجموعة المالكة المستحوِذة.

بموجب اتفاقية النقلة (Rollover Agreement) السارية وقت الاندماج، قامت الشخص المُبلغ عن نفسه بنقل الأسهم العادية التي كان يمتلكها سابقًا وأوراق التفضيل من سلسلة أ، وسلسلة ب إلى NH Holdings 2025 SPV, L.P. مقابل وحدات مماثلة للمشتري الخاص، مما أدى إلى تصريف الأسهم العامة المبلغ عنها. وقّع النموذج من قبل وكيل نيابة عن الشخص المُبلغ ويوثّق التغير في الملكية المستفيدة المرتبطة بالاندماج وبصفقة النقل.

NeueHealth, Inc. (NEUE) 报告了第16部分 Form 4,显示董事 Kedrick D. Adkins Jr. 已在交易日 10/02/2025 处置了 16,443 股普通股,交易后持有的公开普通股为 0 股。 filing 解释称,在 10/02/2025,公司完成了一项合并,NH Holdings 2025, Inc. 收购了发行人,发行人因此成为收购方控股股东的全资子公司。

在合并时生效的 Rollover Agreement 下,报告人将先前持有的普通股及 Serie A 和 Serie B 优先股注入 NH Holdings 2025 SPV, L.P.,以换取私有买方的相应单位,从而产生了公开股的处置。该表格由代理人代表报告人签署,记录了与合并及滚存交易相关的受益所有权变动。

Positive
  • Insider retained economic interest via exchange into NH Holdings units under the Rollover Agreement
  • Transaction documented and reported on Form 4 with attorney-in-fact signature, indicating procedural compliance
Negative
  • Public holding reduced to zero for the reporting director after disposition of 16,443 shares on 10/02/2025
  • Company became a wholly-owned private subsidiary, which may reduce future public disclosures and liquidity for former public shares

Insights

Director converted public equity to private buyer units during the merger.

The filing shows the issuer merged into a Merger Sub controlled by private funds and became a wholly-owned subsidiary of NH Holdings 2025, Inc. The reporting person exchanged public common and preferred stock for private equity units under a Rollover Agreement, which explains the reported disposition of 16,443 public shares on 10/02/2025.

This reduces the public float while preserving economic exposure via private units; watch for any future disclosures about unit rights or liquidity provisions that affect value conversion timing over the next 12 months.

Form 4 documents a compliant Section 16 disclosure tied to a merger and rollover.

The report clarifies that the transaction was effected under a merger agreement and a rollover agreement, and the Form 4 was signed by an attorney-in-fact, indicating procedural compliance for insider reporting. It records that the reporting person now has no direct public common shares following the effective merger.

Investors should note the change in beneficial ownership status and that future public disclosures may be limited now that the issuer is a private subsidiary; review any follow-up filings or investor communications within the typical merger post-close period.

NeueHealth, Inc. (NEUE) ha riportato un modulo della Sezione 16, Modulo 4 che mostra che il direttore Kedrick D. Adkins Jr. ha registrato una disposizione di 16,443 azioni ordinarie in data 10/02/2025 e ora detiene 0 azioni delle azioni ordinarie pubbliche a seguito della transazione. La comunicazione spiega che in 10/02/2025 la società ha completato una fusione in cui NH Holdings 2025, Inc. ha acquisito l'emittente e quest'ultimo è diventato una controllata interamente posseduta della capogruppo acquirente.

Sotto un Rollover Agreement efficace al momento della fusione, la persona che riporta ha conferito azioni ordinarie precedentemente detenute e azioni privilegiate di Serie A e Serie B in NH Holdings 2025 SPV, L.P. in cambio di unità corrispondenti del comprador privato, risultando nella disposizione pubblica delle azioni riportate. Il modulo è firmato da un procuratore-in-fatto per conto della persona che riporta e documenta la variazione della proprietà beneficiaria legata all'operazione di fusione e rollover.

NeueHealth, Inc. (NEUE) informó de un Formulario 4 de la Sección 16 que muestra que el director Kedrick D. Adkins Jr. registró una disposición de 16,443 acciones comunes en la fecha 10/02/2025 y ahora posee 0 acciones de las acciones comunes públicas tras la transacción. El escrito explica que en 10/02/2025 la empresa completó una fusión en la que NH Holdings 2025, Inc. adquirió al emisor y este pasó a ser una subsidiaria de propiedad total de la empresa adquirente.

Con un Rollover Agreement vigente en el momento de la fusión, la persona que reporta aportó acciones comunes previamente poseídas y acciones preferentes Serie A y Serie B a NH Holdings 2025 SPV, L.P. a cambio de unidades correspondientes del comprador privado, resultando en la disposición de las acciones públicas reportadas. El formulario está firmado por un apoderado en nombre de la persona que reporta y documenta el cambio de titularidad beneficiaria vinculado a la fusión y al acuerdo de rollover.

NeueHealth, Inc. (NEUE)는 섹션 16 폼 4를 통해 이사 Kedrick D. Adkins Jr.가 16,443 주의 보통주를 매각한 것을 기록했으며 거래 이후 공개 보통주를 0 주 보유하게 되었음을 보고했습니다. 본 공시는 10/02/2025에 NH Holdings 2025, Inc.가 발행자를 인수했고 발행자가 인수 자회사인 인수 모회사의 wholly-owned 자회사가 되었음을 설명합니다.

합병 시점에 발효된 Rollover Agreement에 따라 보고자는 이전에 보유하던 보통주와 시리즈 A 및 시리즈 B 우선주를 NH Holdings 2025 SPV, L.P.에 기여하고, 이에 상응하는 비공개 매수자의 유닛을 받았으며, 이로 인해 보고된 공개 주식 처분이 발생했습니다. 본 양식은 보고자 대리인에 의해 서명되었으며 합병 및 롤오버 거래와 관련된 수익 소유권의 변화를 문서화합니다.

NeueHealth, Inc. (NEUE) a déclaré, dans un Formulaire 4 de la Section 16, qu’un administrateur, Kedrick D. Adkins Jr., a enregistré une cession de 16 443 actions ordinaires à la date 10/02/2025 et ne détient désormais plus aucune action des actions ordinaires publiques à la suite de la transaction. Le dépôt précise que le 10/02/2025 la société a réalisé une fusion par laquelle NH Holdings 2025, Inc. a acquis l’émetteur et que celui-ci est devenu une filiale entièrement détenue par la société mère acquéreur.

Sous un Rollover Agreement en vigueur au moment de la fusion, la personne déclarant a apporté des actions ordinaires détenues précédemment ainsi que des actions privilégiées de série A et B dans NH Holdings 2025 SPV, L.P. en échange d’unités correspondantes de l’acheteur privé, ce qui a entraîné la disposition des actions publiques déclarées. Le formulaire est signé par un mandataire agissant au nom de la personne déclarant et documente le changement de propriété bénéficiaire lié à la fusion et à l’opération de rollover.

NeueHealth, Inc. (NEUE) meldete ein Section 16 Form 4, das zeigt, dass Direktor Kedrick D. Adkins Jr. eine Veräußerung von 16.443 Stammaktien am 10/02/2025 registrierte und infolgedessen 0 Aktien der öffentlichen Stammaktien nach der Transaktion hält. Die Einreichung erklärt, dass am 10/02/2025 das Unternehmen eine Fusion abgeschlossen hat, bei der NH Holdings 2025, Inc. den Emittenten erworben hat und dieser eine vollständig Tochtergesellschaft der erwerbenden Dachgesellschaft wurde.

Unter einer zum Zeitpunkt der Fusion wirksamen Rollover Agreement hat die meldende Person zuvor gehaltene Stammaktien sowie Serie-A- und Serie-B-Privat-Anteile in NH Holdings 2025 SPV, L.P. eingebracht und dafür entsprechende Einheiten des privaten Käufers erhalten, was zur gemeldeten Veräußerung der öffentlichen Anteile führte. Das Formular ist von einem Bevollmächtigten im Auftrag der meldenden Person unterzeichnet und dokumentiert die Änderung des wirtschaftlichen Eigentums im Zusammenhang mit der Fusion und der Rollover-Transaktion.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ADKINS KEDRICK D JR

(Last) (First) (Middle)
C/O NEUEHEALTH, INC.
9250 NW 36TH ST SUITE 420

(Street)
DORAL FL 33178

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NeueHealth, Inc. [ NEUE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/02/2025 D(1) 16,443 D (2) 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On October 2, 2025, NH Holdings 2025, Inc. ("Parent"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and NH Holdings Acquisition 2025, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), dated as of December 23, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc.
2. Pursuant to the Rollover Agreement, dated as of August 19, 2025 (the "Rollover Agreement"), entered into by and among NH Holdings 2025 SPV, L.P. ("Holdings"), NH Holdings 2025, Inc., NH Holdings Acquisition 2025, Inc. and the Reporting Person, the Reporting Person contributed its shares of Issuer common stock, Series A Convertible Perpetual Preferred Stock ("Series A Preferred Stock") and Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") to Holdings in exchange for Holdings common units, series A preferred units and series B preferred units on a one for one basis in accordance with the Rollover Agreement, and effective as of the effective time of the Merger (the "Effective Time").
Remarks:
/s/ Eric Halverson For Kedrick D. Adkins, Jr., Attorney-in-Fact 10/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 filed for NeueHealth (NEUE) disclose?

The Form 4 shows a disposition of 16,443 common shares by director Kedrick D. Adkins Jr. on 10/02/2025, resulting in 0 public shares beneficially owned.

Why were the shares disposed of according to the filing for NEUE?

The filing explains the shares were contributed under a Rollover Agreement in connection with a merger where NH Holdings 2025, Inc. acquired the issuer and the reporting person received private units in exchange.

Does the Form 4 indicate the company is still publicly traded (NEUE)?

No. The filing states the issuer merged into a Merger Sub and became a wholly-owned subsidiary of NH Holdings 2025, Inc., indicating the company is no longer a standalone public company.

Who executed the Form 4 on behalf of the reporting person?

The Form 4 is signed by Eric Halverson as attorney-in-fact for Kedrick D. Adkins, Jr., dated 10/06/2025.

What securities were exchanged under the Rollover Agreement?

The reporting person contributed common stock and Series A and Series B Convertible Perpetual Preferred Stock in exchange for corresponding common and preferred units of NH Holdings 2025 SPV, L.P.
NeueHealth Inc

NYSE:NEUE

NEUE Rankings

NEUE Latest News

NEUE Latest SEC Filings

NEUE Stock Data

60.94M
7.28M
9.45%
58.37%
0.14%
Healthcare Plans
Hospital & Medical Service Plans
Link
United States
DORAL